Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
Lin HM, Mak B, Yeung N, Huynh K, Meikle TG, Mellett NA, Kwan EM, Fettke H, Tran B, Davis ID, Mahon KL, Zhang A, Stockler MR, Briscoe K, Marx G, Crumbaker M, Stricker PD, Du P, Yu J, Jia S, Scheinberg T, Fitzpatrick M, Bonnitcha P, Sullivan DR, Joshua AM, Azad AA, Butler LM, Meikle PJ, Horvath LG.
Lin HM, et al. Among authors: mellett na.
EBioMedicine. 2021 Oct;72:103625. doi: 10.1016/j.ebiom.2021.103625. Epub 2021 Oct 14.
EBioMedicine. 2021.
PMID: 34656931
Free PMC article.